Skip to content

Gregory M. Lubiniecki

Merck & Co., Inc., Rahway, NJ, USA (United States)

2 papers in the Anchorcite directory, published between 2015 and 2016, cited 16,570 times in total.

Research topics

Frequent co-authors

  • Rina Hui · 2 papers
  • Reshma A. Rangwala · 2 papers
  • Martin Reck · 1 paper
  • Delvys Rodríguez‐Abreu · 1 paper
  • Andrew George Robinson · 1 paper
  • Tibor Csőszi · 1 paper
  • Andrea Fülöp · 1 paper
  • Maya Gottfried · 1 paper

Papers

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations

    BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3…

  2. Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations

    BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…

Metadata from OpenAlex (CC0).